Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person’s chance ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

In conclusion, hope for more efficient, individualized, and secure therapies may come from continuing research and breakthroughs in novel diabetes treatment targets. These developments are at the ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...